

Virtual Consult: Current Cases and Emerging Research in the Management of Multiple Myeloma, Hodgkin and Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Results of the Phase III SWOG-S0777 trial evaluating lenalidomide/dexamethasone with or without bortezomib for patients with previously untreated MM without an intent for immediate ASCT demonstrated significant improvement in _____ with the addition of bortezomib.
 - a. Overall survival
 - b. Progression-free survival (PFS)
 - c. Both a and b
 - d. Neither a nor b
2. Which of the following oral proteasome inhibitors is FDA approved for the treatment of MM?
 - a. Ixazomib
 - b. Oprozomib
 - c. Both a and b
 - d. Neither a nor b
3. Results of the Phase III IFM 2009 trial evaluating early ASCT versus additional cycles of lenalidomide/bortezomib/dexamethasone (RVd) after RVd induction therapy for newly diagnosed MM demonstrated a PFS advantage with _____.
 - a. Additional cycles of RVd
 - b. Early ASCT
 - c. Neither, PFS was equivalent on each arm
4. In the Phase III POLLUX and CASTOR studies, the addition of daratumumab to which of the following regimens for R/R MM significantly improved PFS?
 - a. Bortezomib/dexamethasone
 - b. Lenalidomide/dexamethasone
 - c. Both a and b
 - d. Neither a nor b
5. The combination of elotuzumab and lenalidomide/dexamethasone was recently FDA approved for _____.
 - a. Patients with newly diagnosed MM
 - b. Patients with MM who have received 1 to 3 prior therapies
 - c. Both a and b
6. Which of the following statements is true of venetoclax in the treatment of CLL?
 - a. It acts by inhibiting Bcl-2
 - b. It is not effective in patients with del(17p) CLL
 - c. It can cause tumor lysis syndrome
 - d. All of the above
 - e. Both a and c
7. What is the mechanism of action of acalabrutinib (ACP-196)?
 - a. Antibody-drug conjugate
 - b. BTK inhibitor
 - c. Immunomodulatory drug
 - d. Proteasome inhibitor
8. Nivolumab was recently approved by the FDA for patients with classical HL that has relapsed or progressed after _____.
 - a. ASCT
 - b. Post-transplant brentuximab vedotin
 - c. Both a and b
9. Which of the following agents is classified as a PI3 kinase inhibitor?
 - a. Copanlisib
 - b. Daratumumab
 - c. Elotuzumab
 - d. Idelalisib
 - e. All of the above
 - f. Both b and c
 - g. Both a and d
10. Single-agent lenalidomide has demonstrated preferential activity in which of the following phenotypes of DLBCL?
 - a. Germinal center B-cell (GBC) DLBCL
 - b. Activated B-cell DLBCL (non-GBC DLBCL)
 - c. Neither, lenalidomide activity is equivalent in each phenotype